Skip to Content

Rydex Health Care H RYHAX

Medalist Rating as of | See Rydex Investment Hub
  • NAV / 1-Day Return 36.07  /  −0.11 %
  • Total Assets 23.7 Mil
  • Adj. Expense Ratio
    1.650%
  • Expense Ratio 1.650%
  • Distribution Fee Level High
  • Share Class Type No Load
  • Category Health
  • Investment Style Large Blend
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield
  • Turnover 268%

USD | NAV as of May 17, 2024 | 1-Day Return as of May 17, 2024, 10:16 PM GMT+0

Morningstar’s Analysis RYHAX

Will RYHAX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Rydex Health Care H's Average Process Pillar and People Pillar ratings result in a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RYHAX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

3.90 965,448
Healthcare

UnitedHealth Group Inc

3.31 817,739
Healthcare

Johnson & Johnson

3.00 741,911
Healthcare

Merck & Co Inc

2.88 712,662
Healthcare

AbbVie Inc

2.77 685,971
Healthcare

Thermo Fisher Scientific Inc

2.24 555,056
Healthcare

Abbott Laboratories

2.07 512,379
Healthcare

Danaher Corp

1.98 488,702
Healthcare

Pfizer Inc

1.96 484,487
Healthcare

Amgen Inc

1.95 482,775
Healthcare